111 Capital Invests $299,000 in AstraZeneca PLC (NASDAQ:AZN)

111 Capital bought a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,564 shares of the company's stock, valued at approximately $299,000.

Other large investors have also modified their holdings of the company. Banque Transatlantique SA acquired a new position in shares of AstraZeneca in the fourth quarter valued at $26,000. CoreCap Advisors LLC grew its position in AstraZeneca by 31.8% in the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after acquiring an additional 155 shares during the period. Crews Bank & Trust bought a new stake in AstraZeneca in the fourth quarter valued at $55,000. Golden State Wealth Management LLC bought a new stake in AstraZeneca in the fourth quarter valued at $55,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in AstraZeneca in the fourth quarter valued at $55,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Price Performance

Shares of AZN stock traded down $0.11 during trading hours on Tuesday, hitting $71.82. 4,514,542 shares of the company's stock were exchanged, compared to its average volume of 5,196,628. The stock's 50-day moving average is $69.35 and its 200-day moving average is $69.81. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. The stock has a market cap of $222.73 billion, a price-to-earnings ratio of 31.78, a price-to-earnings-growth ratio of 1.42 and a beta of 0.38. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. The company had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The business's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.06 earnings per share. As a group, research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on AZN shares. BNP Paribas started coverage on AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a research report on Thursday, February 13th. Finally, Morgan Stanley started coverage on AstraZeneca in a research report on Wednesday, February 12th. They issued an "overweight" rating on the stock. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $85.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.